A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF BA3021 IN PATIENTS WITH ADVANCED SOLID TUMORS
Sponsor: |
BioAtla LLC |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS0590 |
U.S. Govt. ID: |
NCT03504488 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
BioAtla (the sponsor of the clinical trial) is studying BA3021 as a potential treatment for varieties of cancers including but not limited to lung, triple negative breast cancer and soft tissue sarcoma. The purpose of this research study is to test the safety of different doses of BA3021 and to find out what effects, good and/or bad, it has on the body and the cancer.
This study is closed
Investigator
Brian Henick, MD
Are you 18 years of age or older? |
Yes |
No |
Do you have lung, triple negative breast cancer or soft tissue sarcoma? |
Yes |
No |
Does your cancer continue to grow despite therapy? Or, are you not eligible for therapy or refuse standard of care therapy? |
Yes |
No |